These biomarkers, including HIF-1α, VEGF, carbonic anhydrase IX (CAIX), and glucose transporter 1 (GLUT-1), have the potential to serve as diagnostic tools, prognostic indicators, and therapeutic targets in breast cancer. This evidence concerns the gene HIF1A and breast carcinoma.